The pursuit of a healthy life has been a trendy and serious issue for decades.
Undoubtedly, emerging antibiotics will be a lighthouse to guide all mankind towards happiness.
Dr.George has involved in biomedical research field for over a decade, specializing in the research and development of new compounds and new drugs. George has achieved some impressive milestones after graduated from the Department of Plant Pathology, National Chung Hsing University:
2018-Successfully transferred the plant protection Streptomyces Padanus PMS-702 composition and preparation and further improved it into the core extraction technology-ExtrOTM.Established Anti-Microbial Savior BioteQ Co., Ltd. (AMS BioteQ).
2021-AMS BioteQ joined the emerging stock market successfully in Dec.
CEO Calvin holds an MBA in Business Administration with a focus on Finance from California State Polytechnic University, Pomona. With expertise in venture capital, he has served as a director of the Securities Over-the-Counter Market and as a board member of the Securities and Futures Investors Protection Center in Taiwan. As the Chairman of Taiwan Venture Capital and Taishin Securities Venture Capital, he has led companies to growth and innovation in a competitive market.
Drug Development| Instrumentation| Quality Control| GLP
Dr. Ian earned his Ph.D from the Institute of Food Science and Technology at National Taiwan University. His expertise includes new drug development, instrumental analysis, quality control, and polysaccharide testing. He holds internationally recognized certifications including ISO/IEC 17025 and GLP. Dr. Chang's blend of academic rigor and hands-on industry experience strengthens our capabilities in pharmaceutical innovation and food safety. His exceptional leadership in cross-functional integration and quality enhancement directly supports our R&D efficiency, accelerates time-to-market, and technological innovation, therefore contributing significantly to the company's competitive edge.
Business Strategy | International Market Development | Brand Management | Biotechnology
Felix Tsai, Chief Business Officer, holds a bachelor's degree in Horticulture from National Taiwan University and a master's degree in Oral Biology from the same institution. His academic background spans plant science and medical science, with extensive experience in the biotechnology and digital health industries.
He oversees AMS BioteQ's business strategy and market development, covering product lines in smart agriculture, medical devices, and skincare. Mr. Tsai brings strong expertise in brand positioning, regulatory market entry, and cross-border channel development. He actively drives the Company's expansion across Taiwan, Southeast Asia, Japan, and the United States, leveraging integrated commercial execution to support sustainable growth.
ERP Implementation | Internal Control Design | Cost Accounting Systems | IPO Advisory
Nicolas Liu, Head of Finance Management Department, holds a Master’s degree in Financial Management from National Kaohsiung First University of Science and Technology. He specializes in the establishment of corporate financial systems and the optimization of operational management frameworks.
He has extensive practical experience in ERP system implementation, internal control system design and improvement tracking, cost accounting system development, and share registration management. He is well-versed in corporate financial processes and audit mechanisms and has participated in the development and enhancement of corporate governance structures.
In addition, he has experience in IPO application and advisory services, assisting companies in improving financial transparency and preparing for capital market entry. He plays a key role in integrating financial information and internal control systems to ensure compliance with internal management standards and regulatory requirements, supporting stable corporate development and long-term strategic objectives.
Ms. Hsu Li-Yu, Director, graduated from National Chung Hsing University. She specializes in internal control, auditing, and IPO guidance, with expertise in accounting and shareholder services. Her leadership drives corporate efficiency, compliance, and growth.
We have established an organizational structure centered on cross-functional collaboration, integrating key functions including R&D, manufacturing, quality assurance, regulatory affairs, and marketing. This creates a fully integrated operational system spanning from technology development to market application.
In the technology development domain, our teams focus on microbial control, active material design, and translational research, continuously driving the transformation of fundamental science into practical and applicable solutions.
In manufacturing and quality management, we implement standardized production processes and stringent quality control systems to ensure high standards of stability, safety, and consistency across all products.
Our regulatory and validation team is responsible for compliance strategy and alignment with international regulations, ensuring that our technologies can be effectively adapted to diverse markets and application environments.
Meanwhile, our marketing and business development teams focus on market insights, application expansion, and industry collaboration, translating technological outcomes into commercially valuable solutions.
Through close cross-departmental collaboration, we have built an end-to-end value chain—from research and development to product realization and market deployment—enabling innovation to be reliably translated into real-world applications and continuously scaled.
